Gianlorenço Anna Carolyna, Camargo Lucas, Fernandes Elayne Borges, Pichardo Elly, Yeh Huan Jui, Hazer-Rau Dilana, Storz Rafael, Fregni Felipe
Spaulding Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA 02115, USA.
Neurosciences Laboratory, Physical Therapy Department, Federal University of Sao Carlos, Sao Carlos 13565-905, Brazil.
Bioengineering (Basel). 2025 Jul 17;12(7):773. doi: 10.3390/bioengineering12070773.
Parkinson's Disease (PD) is a progressive neurodegenerative disorder marked by motor and non-motor symptoms, including cognitive decline, mood disturbances, and sensory deficits. While dopaminergic treatments remain the gold standard, they present long-term side effects and limited impact on non-motor symptoms. Transcranial Pulse Stimulation (TPS) has emerged as a promising adjunct therapy in neurological and psychiatric conditions, but its effects in PD remain underexplored. This open-label, single-arm trial protocol involves 14 PD participants and outlines a personalized 12-session treatment approach combined with a homogeneously distributed TPS intervention among patients with PD. The approach addresses the subject's most prominent symptoms, as identified through validated clinical assessments, encompassing domains related to both motor and non-motor symptoms. Over 2.5 months, besides the intervention sessions, the 14 participants will undergo an MRI brain scan, a baseline assessment, a post-treatment assessment, and a 1-month follow-up assessment. The study aims to determine whether personalized TPS is a feasible and safe intervention and whether it improves PD symptoms across multiple functional domains. This study represents the first structured attempt to evaluate a multimodal, personalized TPS intervention in patients with PD. It addresses gaps in current treatment approaches and may support the development of future strategies for integrated, symptom-targeted neuromodulation.
帕金森病(PD)是一种进行性神经退行性疾病,其特征为运动和非运动症状,包括认知衰退、情绪障碍和感觉缺陷。虽然多巴胺能治疗仍然是金标准,但它们存在长期副作用,且对非运动症状的影响有限。经颅脉冲刺激(TPS)已成为神经和精神疾病中有前景的辅助治疗方法,但其在帕金森病中的作用仍未得到充分探索。本开放标签、单臂试验方案纳入了14名帕金森病参与者,并概述了一种个性化的12节治疗方法,同时在帕金森病患者中进行均匀分布的TPS干预。该方法针对通过经验证的临床评估确定的受试者最突出症状,涵盖与运动和非运动症状相关的领域。在2.5个月的时间里,除了干预疗程外,这14名参与者还将接受脑部MRI扫描、基线评估、治疗后评估和1个月的随访评估。该研究旨在确定个性化TPS是否是一种可行且安全的干预措施,以及它是否能改善多个功能领域的帕金森病症状。本研究是评估帕金森病患者多模式、个性化TPS干预的首次结构化尝试。它填补了当前治疗方法的空白,并可能支持未来针对症状的综合神经调节策略的发展。